Filtered By:
Drug: Tekturna

This page shows you your search results in order of date.

Order by Relevance | Date

Total 20 results found since Jan 2013.

First-line diuretics versus other classes of antihypertensive drugs for hypertension
CONCLUSIONS: When used as first-line agents for the treatment of hypertension, thiazides and thiazide-like drugs likely do not change total mortality and likely decrease some morbidity outcomes such as cardiovascular events and withdrawals due to adverse effects, when compared to beta-blockers, calcium channel blockers, ACE inhibitors, and alpha-blockers.PMID:37439548 | DOI:10.1002/14651858.CD008161.pub3
Source: Cochrane Database of Systematic Reviews - July 13, 2023 Category: General Medicine Authors: Marcia Reinhart Lorri Puil Douglas M Salzwedel James M Wright Source Type: research

Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM ‐HF and ATMOSPHERE
ConclusionsIn HF, the impact of multimorbidity differed at the individual patient and population level, depending on the prevalence of and the risk related to each comorbidity, and the interaction between individual comorbidities. Patients with coexistent PAD and stroke were at greatest individual risk whereas, from a population perspective, coexistent CKD and hypertension mattered most.
Source: European Journal of Heart Failure - April 25, 2023 Category: Cardiology Authors: Pooja Dewan, Jo ão Pedro Ferreira, Jawad H. Butt, Mark C. Petrie, William T. Abraham, Akshay S. Desai, Kenneth Dickstein, Lars Køber, Milton Packer, Jean L. Rouleau, Simon Stewart, Karl Swedberg, Michael R. Zile, Scott D. Solomon, Pardeep Tags: Research Article Source Type: research

Impact of multimorbidity on mortality in HFrEF: Which comorbidities matter most? – An analysis of PARADIGM‐HF and ATMOSPHERE
ConclusionsIn HF, the impact of multimorbidity differed at the individual-patient and population level, depending on the prevalence of and the risk related to each comorbidity, and the interaction between individual comorbidities. Patients with co-existent PAD and stroke were at greatest individual risk whereas, from a population perspective, co-existent CKD and hypertension mattered mostThis article is protected by copyright. All rights reserved.
Source: European Journal of Heart Failure - April 17, 2023 Category: Cardiology Authors: Pooja Dewan, Jo ão P Ferreira, Jawad H Butt, Mark C Petrie, William T Abraham, Akshay S. Desai, Kenneth Dickstein, Lars Køber, Milton Packer, Jean L Rouleau, Simon Stewart, Karl Swedberg, Michael R Zile, Scott D Solomon, Pardeep S Jhund, Tags: Research Article Source Type: research

Central Application of Aliskiren, a Renin Inhibitor, Improves Outcome After Experimental Stroke Independent of Its Blood Pressure Lowering Effect
Epidemiological studies suggest that pharmacological reduction of systemic hypertension lowers incidence and severity of stroke. However, whether the reduction of blood pressure per se or the compounds used to reduce hypertension are responsible for this effect received little attention. In the current study we therefore aimed to investigate whether Aliskiren, a renin-inhibitor used to treat arterial hypertension, may improve outcome in a mouse model of ischemic stroke when applied centrally and in a dose not affecting blood pressure. Male C57BL/6 mice received 0.6, 2.0, or 6.0 µg Aliskiren or vehicle by intracerebroven...
Source: Frontiers in Neurology - September 3, 2019 Category: Neurology Source Type: research

Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy Original Research Articles
Conclusions Despite younger age, less comorbidity, and comprehensive use of conventional HF therapies, patients with Chagasic HF with reduced ejection fraction continue to have worse quality of life and higher hospitalization and mortality rates compared with other etiologies. Clinical Trial Registration PARADIGM-HF: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255; ATMOSPHERE: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00853658.
Source: Circulation: Heart Failure - November 15, 2017 Category: Cardiology Authors: Shen, L., Ramires, F., Martinez, F., Bodanese, L. C., Echeverria, L. E., Gomez, E. A., Abraham, W. T., Dickstein, K., Kober, L., Packer, M., Rouleau, J. L., Solomon, S. D., Swedberg, K., Zile, M. R., Jhund, P. S., Gimpelewicz, C. R., McMurray, J. J. V., o Tags: Heart Failure Original Research Articles Source Type: research

Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial
Conclusions/interpretationWe identified three questions from the MNSI that provide additional prognostic information for individuals with type 2 diabetes and CKD and/or CVD. If externally validated, these questions may be integrated into the clinical history to augment prediction of CV events in high-risk individuals with type 2 diabetes.
Source: Diabetologia - November 3, 2017 Category: Endocrinology Source Type: research

Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial
ASN 2016 High Impact Clinical Trial Johannes F. Mann, Kristine Brown Fandsen, Gilbert Daniels, Peter Kristensen, Michael Nauck, Steve Nissen, Stuart Pocock, Neil Poulter, Soren Rasmussen, William Steinberg, Mette Stockner, Bernard Zinman, Florian Baeres, Richard Bergenstal, Steve Marso, John Buse. Erlangen, Germany. Liraglutide, as compared to placebo, was studied in a RCT of 9340 high-risk type 2 diabetic patients to examine the impact on the primary composite outcome of nonfatal MI, nonfatal stroke, and cardiovascular death.  The secondary renal endpoint (composite of doubling serum creatinine, ESRD, death due to renal ...
Source: Nephrology Now - November 19, 2016 Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Clinical Trial Results Conference Alert Source Type: research

Protective Effect of Aliskiren in Experimental Ischemic Stroke: Up-Regulated p-PI3K, p-AKT, Bcl-2 Expression, Attenuated Bax Expression.
This study aimed to investigate the role of ALK and its potential mechanism in cerebral ischemia. C57/BL6 mice were subjected to transient middle cerebral artery occlusion (tMCAO) and treated for 5 days with Vehicle or ALK (10 or 25 mg/kg per day via intragastric administration), whereas Sham-operated animals served as controls. Treatment with ALK significantly improved neurological deficits, infarct volume, brain water content and Nissl bodies after stroke (P < 0.05), which did not affect systemic blood pressure. Furthermore, the protection of ALK was also related to decreased levels of apoptosis in mice by enhance...
Source: Neurochemical Research - May 13, 2016 Category: Neuroscience Authors: Miao J, Wang L, Zhang X, Zhu C, Cui L, Ji H, Liu Y, Wang X Tags: Neurochem Res Source Type: research

Two ‐Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non‐Interventional Prospective Study
The authors investigated the long‐term effectiveness and safety of aliskiren (ALIS) with particular attention on its association with dual blockade of the renin‐angiotensin system (RAS). The open, prospective 3A Registry (N=8723) in Germany assigned patients in a 4:1:1 ratio to ALIS, angiotensin‐converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), or non‐RAS drugs. Patients taking ALIS compared with those taking ACE inhibitors/ARBs or non‐RAS had more comorbidities and risk factors, were taking more antihypertensive agents, and had higher blood pressure (BP) values at entry. At 2 years, BP...
Source: The Journal of Clinical Hypertension - November 13, 2015 Category: Cardiology Authors: Uwe Zeymer, Ralf Dechend, Thomas Riemer, Evelin Deeg, Jochen Senges, David Pittrow, Roland Schmieder, Tags: Original Paper Source Type: research

Two‐Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non‐Interventional Prospective Study
The authors investigated the long‐term effectiveness and safety of aliskiren (ALIS) with particular attention on its association with dual blockade of the renin‐angiotensin system (RAS). The open, prospective 3A Registry (N=8723) in Germany assigned patients in a 4:1:1 ratio to ALIS, angiotensin‐converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), or non‐RAS drugs. Patients taking ALIS compared with those taking ACE inhibitors/ARBs or non‐RAS had more comorbidities and risk factors, were taking more antihypertensive agents, and had higher blood pressure (BP) values at entry. At 2 years, BP...
Source: The Journal of Clinical Hypertension - November 1, 2015 Category: Cardiology Authors: Uwe Zeymer, Ralf Dechend, Thomas Riemer, Evelin Deeg, Jochen Senges, David Pittrow, Roland Schmieder, Tags: Original Paper Source Type: research

Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS
Aliskiren previously was found to have potentially harmful effects in diabetic individuals prescribed concomitant angiotensin converting enzyme inhibitors (ACEI) or angiotenisn receptor antagonists (ARB). We explored potential effects of aliskiren on coronary atheroma progression and major adverse cardiovascular events (MACE: death/non-fatal MI/non-fatal stroke/hospitalization for heart failure/hospitalization for ACS/arterial revascularization) in patients with and without diabetes mellitus (DM).
Source: Atherosclerosis - October 21, 2015 Category: Cardiology Authors: Rishi Puri, Steven E. Nissen, Venu Menon, Mingyuan Shao, Amy Hsu, George L. Bakris, John J.P. Kastelein, Bryan Williams, Juergen Armbrecht, Patrick Brunel, Yu Kataoka, Stephen J. Nicholls Source Type: research

Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial
Conclusion The majority of deaths occurred in patients who did not experience a non-fatal CV or renal event, although the risk of death was higher following an event. Our findings illustrate continuing opportunities to reduce morbidity and mortality in patients with type 2 diabetes.
Source: European Heart Journal - September 21, 2015 Category: Cardiology Authors: Jhund, P. S., McMurray, J. J. V., Chaturvedi, N., Brunel, P., Desai, A. S., Finn, P. V., Haffner, S. M., Solomon, S. D., Weinrauch, L. A., Claggett, B. L., Pfeffer, M. A. Tags: Prevention and epidemiology Source Type: research

Aliskiren and losartan trial in non-diabetic chronic kidney disease
Conclusion: This study in non-diabetic CKD patients showed that combination therapy with aliskiren and ARB was as efficacious as aliskiren alone and ARB alone. There was one patient who developed a non-fatal stroke in the combined aliskiren and ARB group while the other two groups had none.
Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS - December 12, 2014 Category: Biomedical Science Authors: Woo, K.-T., Choong, H.-L., Wong, K.-S., Tan, H.-K., Foo, M., Fook-Chong, S., Lee, E. J., Anantharaman, V., Lee, G. S., Chan, C.-M. Tags: Original Articles Source Type: research

No Increase in Adverse Events During Aliskiren Use Among Ontario Patients Receiving Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers
Conclusions Among community-dwelling patients aged 66 years and older receiving therapy with an ACEi or an ARB, aliskiren use was not associated with hospitalization for hyperkalemia, AKI, or stroke.
Source: Canadian Journal of Cardiology - November 1, 2014 Category: Cardiology Source Type: research